For the current quarter, BioXcel Therapeutics Inc (NASDAQ:BTAI) is expected to declare Earnings Per Share (EPS) of ($0.80) estimates Wall Street brokerages as reported by Zacks Investment Research. No estimates have been presented for the company by analysts. The highest estimated EPS is ($0.58) and the lowest is ($0.93). In the previous year for the same quarter, BioXcel Therapeutics registered ($0.57) earnings per share. This indicates a 40.4% negative year-over-year growth. On Thursday, 12th November, the company will announce the results of the next earnings.
BioXcel Therapeutics (NASDAQ:BTAI) EPS Estimates
Analysts estimate that the full-year earnings for the current year of BioXcel Therapeutics (NASDAQ:BTAI) will be ($3.38). The estimated EPS range will vary from ($3.73) to ($3.00), reports Zacks. According to analysts, the estimated earnings per share of the company for the next financial year will be ($3.29). ($4.61) to ($2.43) is the anticipated EPS range.
On Friday, 14th August, BioXcel Therapeutics announced its quarterly earnings report. For the quarter, BioXcel Therapeutics (NASDAQ:BTAI) reported earnings per share of ($1.06) as opposed to the consensus estimates made by analysts of ($0.74) by ($0.32).
On Monday,13th July, the price target on the company was increased from $53.00 to $63.00 by Bank of America. It also changed the company’s rating to ‘buy.’
On Wednesday, 2nd September issued a research report mentioning that they have assumed coverage on BioXcel Therapeutics. A price target of $82.00 was set and a ‘buy’ rating was given by the bank. On Monday,17th August, HC Wainwright reduced the price objective on BioXcel Therapeutics (NASDAQ:BTAI) from $200.00 to $175.00 and issued a ‘buy’ rating. Canaccord Genuity decreased the price target from $120.00 to $108.00 and reissued a ‘buy,’ as per a research note issued on Friday, 14th August.
On Monday, 17th August, a research report suggested that BMO Capital Markets reduced the price target on the firm from $104.00 to $95.00. They also issued an ‘outperform’ rating. The stock has been rated with ‘hold’ by one analyst. ‘Buy’ rating has been issued by seven analysts. The consensus rating of BioXcel Therapeutics (NASDAQ:BTAI) is ‘buy’ and the average price target is $95.57.
BioXcel Therapeutics (NASDAQ:BTAI)- Other news
The stakes in the stocks have been recently added or reduced by several big investors. In the 2nd quarter, new shares worth $1,442,000 were acquired by Two Sigma Advisers LP.
In the 2nd quarter, a new stake worth $204,000 was acquired by Principal Financial Group Inc. in BioXcel Therapeutics (NASDAQ:BTAI). There was a 0.6% improvement in Nuveen Asset Management LLC’s position in the company during the second quarter. Nuveen Asset Management LLC acquired 861 new shares and now owns 155,007 shares of BioXcel Therapeutics’ stocks that are worth $8,217,000.